{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-188522","form_type":"8-K","ticker":"NGNE","cik":"0001404644","company_name":"Neurogene Inc.","filed_at":"2023-07-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.807284+00:00","generated_at":"2026-06-13T06:58:16.833712+00:00","sec_items":["1.01","3.02","5.01","5.02","7.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Neoleukin to merge with Neurogene; Neurogene stockholders to own ~84% of combined co.","bullets":["Neoleukin stockholders will own ~16% of combined company; Neurogene stockholders ~84% on as-converted basis.","Concurrent ~$95M private financing from investors to close immediately before merger.","Closing conditions include Neoleukin net cash >= $60M and Neurogene gross proceeds >= $75M from financing.","Post-merger board of 7 directors: 5 designated by Neurogene, 2 by Neoleukin; CVRs for legacy asset proceeds.","Support agreements from ~77% of Neurogene and ~21% of Neoleukin stockholders; 180-day lock-up on shares."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-188522","json":"https://secwatch.observer/filing/0001193125-23-188522.json","markdown":"https://secwatch.observer/filing/0001193125-23-188522.md","text":"https://secwatch.observer/filing/0001193125-23-188522.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1404644/000119312523188522/0001193125-23-188522-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1404644/000119312523188522/d506859d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T06:58:16.833712+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"71f5c20acb19e134c1037c4b709b896c14c8710c","claim":"Neurogene Inc. entered into Agreement and Plan of Merger with Neoleukin Therapeutics, Inc. (effective 2023-07-17).","evidence_excerpt":"On July 17, 2023, Neoleukin Therapeutics, Inc., a Delaware corporation (“Neoleukin”), Project North Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Neoleukin (“Merger Sub”), and Neurogene Inc., a Delaware corporation (“Neurogene”), entered into an Agreement and Plan of Merger (the “Merger Agreement”)","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1404644/000119312523188522/0001193125-23-188522-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"merger"},{"label":"Counterparty","value":"Neoleukin Therapeutics, Inc."},{"label":"Effective","value":"2023-07-17"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}